

Please insert the Sequence Listing attached hereto at Tab B after the Abstract.

### IN THE CLAIMS

Please amend claims 17, 23, and 29 as follows:

01 17. (twice amended) The method of claim 16 wherein said antigen of an HIV-1-subtype D isolate corresponds to a sequence selected from the group consisting of SEQ ID NOs. 29 to 39. 1-11

02 23. (twice amended) The antigen mixture of claim 19 wherein said antigen of an HIV1-subtype D isolate corresponds to a sequence selected from the group consisting of SEQ ID NOs. 29 to 39.

03 25. (twice amended) The antigen mixture of claim 19, further comprising an antigen from epitope region I, amino acids 570-584, or epitope region II, amino acids 581-596, of HIV1-subtype O.

04 29. (twice amended) An immunoassay method for detection of an antibody against HIV comprising:  
a. providing a sample suspected of containing an antibody against HIV,  
b. contacting said sample with an antigen comprising a sequence selected from the group consisting of SEQ ID NOs. 29 to 39, said sequence having a minimum length of 7 amino acids, characterized in that said antigen is bound to a label which generates a detectable signal when the antigen is bound to said antibody, and  
c. detecting the signal generated as a measure of said HIV antibody in the sample.

### REMARKS

Claims 16, 17, 19, 23, 25, 29, and 30 are pending and stand rejected. Claims 17, 23, and 29, and portions of the specification have been amended for compliance with the sequence listing requirements of 37 CFR 1.821-1.825. A Statement Supporting the Filing of the Sequence Listing